US 10-Year Treasury Yield at 6% Emerges as New Market Risk Threshold 
Oil Prices Jump 3% as Houthi Attack Revives Supply Fears 
Russian Envoy Dmitriev Heads to US for Ukraine Talks 
Select Water Solutions Shares Surge on $700 Million Pilot Water Deal 
RBI Uses $10 Billion Currency Swaps to Drain Excess Rupee Liquidity 
Akamai Shares Surge on $11.6B Anthropic AI Cloud Deal 
Novo Nordisk Weighs Direct NYSE Listing to Boost U.S. Profile 
China Vanke Shares Jump as Beijing Moves to Ease Debt Pressure 
Microsoft Stock Upgraded as Stifel Sees Stronger Azure Growth 
Oil Prices Surge as U.S.-Iran Diplomacy Hopes Fade 
Trump, Xi Focus on Trade and AI at White House Summit 
Oil Prices Ease as Iran Tensions Clash With Diplomacy Hopes 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
US Dollar Hits Two-Month High as Fed Rate Hike Bets Rise 
JPMorgan Names Lavatelli Japan Chief in Leadership Shake-Up 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
US Backs Musk in Fight Against EU’s €120 Million X Fine 
Add as a preferred source on Google
Samsung Biologics signed a new deal with GSK, formerly GlaxoSmithKline. This will be their second manufacturing deal, and this time the agreement value is $296.1 million.
The amount is said to be almost 30% of the full-year revenue of Samsung last year, which was KRW1.5 trillion or around $1 billion, and the contract with GSK is in effect until the end of 2030. Samsung Biologics is currently the top Contract Manufacturing Organization in the world in terms of capacity, and its latest deal with the said British pharmaceutical industry company is for the supply of biopharma products.
Samsung Biologics and GSK plc confirmed their second collaborative contract late last week. As per The Korea Economic Daily, the biotech unit of the Samsung Group did not disclose the details of the exact products it will make for GSK under their contract.
One of their earlier deals was signed in May 2020, and it was a contract worth $231 million. It was also for the supply of biopharma products for eight years since the contract was made official. To be more specific, this was for the production and delivery of GSK’s Benlysta (belimumab) drug, which is used for the treatment of the autoimmune disease - lupus nephritis.
GSK and Samsung Biologics expanded their deal and signed another contract in August 2020, which was worth $368.1 million. It was a CMO agreement to produce sotrovimab, a SARS-CoV-2 monoclonal antibody that targets the COVID-19 virus.
In any case, the new deal is a remarkable expansion of the business relationship between Samsung Biologics and GSK. They already partnered in several projects, and now larger contracts are coming up
Meanwhile, Fierce Pharma reported that the new agreement comes as Samsung Biologics launches its “Super Plant,” which is also its fourth manufacturing facility. It sits in the company’s huge complex in Incheon, South Korea. It has invested more than $2 billion in the construction of this massive plant as part of its ambitious plan to become a major global player in the contract development and manufacturing organization scene.
